Navigation Links
ENDECE Neural to Present Findings at 2013 Biotech Showcase on NDC-1308 which Induces Remyelination of Demyelinated Axons
Date:12/10/2012

MEQUON, Wis., Dec. 10, 2012 /PRNewswire/ -- ENDECE Neural, LLC (www.endeceneural.com) announced today that the company will be presenting at the 2013 Biotech Showcase in San Francisco, California, January 8th.

The ENDECE Neural presentation, to be given by Dr. James Yarger, CEO, will discuss the company's novel therapeutic for directly inducing remyelination of demyelinated axons to treat neurological diseases such as Multiple Sclerosis (MS).

Currently there are no drugs commercially available for remyelination in MS, or any other disease associated with demyelination. ENDECE Neural may have one of the first compounds with the ability to directly induce remyelination.

"This novel therapeutic could be used either alone or in combination with current immunosuppressant/anti-inflammation therapies," says Dr. Yarger. "We are looking to partner with or license this exciting opportunity to potentially restore function, mobility and independence to those fighting MS." 

About ENDECE Neural, LLC (an ENDECE Company)
ENDECE Neural is the wholly owned subsidiary of ENDECE, LLC. ENDECE Neural was founded in 2011 to focus on the development of what could be the first drug capable of inducing remyelination of damaged nerve axons, and potentially restoring muscle control, mobility and independence to the lives of Multiple Sclerosis patients. ENDECE Neural maintains an exclusive license for the IP from its parent company.

About Biotech Showcase (Innovation – Opportunity – Collaboration)
Now in its fifth year, Biotech Showcase (www.ebdgroup.com/bts) features corporate presentations by 195 innovative life science companies to public and private investors, business development executives and professional advisors who are interested in investment opportunities and collaboration. Biotech Showcase takes place during the week of one of the most important healthcare investor conferences which annually attracts thousands of healthcare and life science business executives to San Francisco in a venue located close to the center of action. To maximize efficiency, all Biotech Showcase participants can schedule one-to-one meetings through EBD Group's online system, partneringONE®. Public and private investors are always invited to attend on a complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life Science Advisors and EBD Group, two organizations that have a long and successful history building programs that meet the needs of the life science industry.


'/>"/>
SOURCE ENDECE Neural, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. First Neurally Controlled, Powered Prosthetic Limb Is 2,109 Steps Closer To Realization
2. Neural implant recovers ability to make decisions
3. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
4. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
5. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
6. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
7. Triangles guide the way for live neural circuits in a dish
8. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
9. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
10. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
11. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology:
(Date:6/16/2016)... The global Biometric ... USD 1.83 billion by 2024, according to a ... proliferation and increasing demand in commercial buildings, consumer ... the market growth.      (Logo: ... of advanced multimodal techniques for biometric authentication and ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
Breaking Biology News(10 mins):